185 related articles for article (PubMed ID: 21278518)
21. Choices--and uncertainties--for women with BRCA mutations.
Couzin J
Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
[No Abstract] [Full Text] [Related]
22. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
[No Abstract] [Full Text] [Related]
24. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal.
Tinelli A; Malvasi A; Leo G; Vergara D; PisanĂ² M; Ciccarese M; Chiuri VE; Lorusso V
Cancer Metastasis Rev; 2010 Jun; 29(2):339-50. PubMed ID: 20405170
[TBL] [Abstract][Full Text] [Related]
25. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
26. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
27. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
28. [Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma].
Schmutzler RK; Kempe A; Kiechle M; Beckmann MW
Dtsch Med Wochenschr; 1999 May; 124(18):563-6. PubMed ID: 10356583
[No Abstract] [Full Text] [Related]
29. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
Agnantis NJ; Paraskevaidis E; Roukos D
Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
[No Abstract] [Full Text] [Related]
30. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
Prucka SK; McIlvried DE; Korf BR
Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
[TBL] [Abstract][Full Text] [Related]
31. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.
Kurian AW
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):72-8. PubMed ID: 19841585
[TBL] [Abstract][Full Text] [Related]
32. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
33. Perspectives in the clinical management of BRCA mutations carriers.
Savarese A; Cognetti F
J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
Brunsvold AN; Wung SF; Merkle CJ
J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
[TBL] [Abstract][Full Text] [Related]
35. Preventing familial breast and ovarian cancer: major research advances with little implication.
Ziogas DE; Katsios CS; Roukos DH
Womens Health (Lond); 2011 Mar; 7(2):135-8. PubMed ID: 21410338
[No Abstract] [Full Text] [Related]
36. Pretest genetic counseling informs patients with BRCA mutation.
Printz C
Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
[No Abstract] [Full Text] [Related]
37. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
38. BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.
Miller-Samuel S; Rosenberg A; Berger A; Gomella L; Loren D; Morris GJ
Semin Oncol; 2011 Oct; 38(5):605-11. PubMed ID: 21943665
[No Abstract] [Full Text] [Related]
39. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
40. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
Paluch-Shimon S; Cardoso F; Sessa C; Balmana J; Cardoso MJ; Gilbert F; Senkus E;
Ann Oncol; 2016 Sep; 27(suppl 5):v103-v110. PubMed ID: 27664246
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]